Fridays’ most revealing evidence disclaimer concerns its advertised “success rate”: the company says that figure measures fulfillment and delivery of paid orders, not clinical outcomes. That distinction frames this review. Public documentation can establish what Fridays advertises, how enrollment works and which obligations appear in its terms. It cannot establish how much weight its patients lose, whether a particular compounded preparation matches a studied product or how reliably an individual will receive care.
The pages consulted October 19, 2026, describe compounded semaglutide and tirzepatide, branded medications, clinical consultations and nutrition support. They also contain overlapping prices and unresolved differences about inclusions, discounts and refunds. For U.S. adults comparing providers, the useful question is therefore not simply whether GLP-1 medicines have research behind them. It is which parts of that research apply to the exact product offered—and whether Fridays’ written service and payment terms are clear enough to evaluate before enrollment.
At a glance
- Platform and clinical responsibility
- Thrive Health Group, Inc. operates Fridays; OpenLoop Healthcare Partners, PC and other networks provide clinical services and retain prescribing discretion.
- Compounded-product disclosure
- Fridays says it does not manufacture compounded medications and discloses that they have not been evaluated or approved by FDA for safety, efficacy or quality.Sources: [8]
- Prices require reconciliation
- The pricing page displays compounded semaglutide from $150/month with annual payment and $249/month month-to-month, plus competing promotional figures.Sources: [6]
- Cancellation deadline
- Fridays must receive a cancellation request at least 72 hours before the next scheduled billing date to avoid another cycle.Sources: [7]
- Marketing is not an outcomes study
- The company defines its advertised success rate as internal fulfillment and delivery performance, not weight-loss effectiveness or individual results.Sources: [8]
Start with what the evidence actually measures
Fridays’ fulfillment disclaimer is unusually consequential. It says the success figure reflects paid orders during the current quarter and can vary with pharmacy capacity, state rules and order details. A delivery measure may help describe operations, but it does not measure weight change, treatment tolerance or sustained health improvement. The consulted documentation does not establish provider-specific clinical outcomes through a controlled study. It should not be read as doing so merely because medicines offered through the platform have recognizable ingredient names.
The same distinction applies to the microdosing page. Fridays discusses possible benefits involving cardiovascular wellness, inflammation, cognition and liver function, while acknowledging that compounded microdose formulations have not specifically been studied for those outcomes. The page also mixes a coming-soon announcement with start buttons and uses inconsistent semaglutide labeling. Those are reasons to request a precise product description and availability confirmation, not evidence that the proposed regimen produces the advertised benefits.
Published trials answer narrower questions than a provider’s marketing page. STEP 1 studied subcutaneous semaglutide in a defined population; SURMOUNT-1 studied subcutaneous tirzepatide under a separate protocol. Neither establishes outcomes for Fridays, its compounded preparations, oral offerings or microdoses. Our guide to why a clinical trial is not a company performance report explains this boundary. Recognizing it does not dismiss the underlying research; it prevents research on one intervention from becoming an unsupported endorsement of another.
| Documentation | What it supports | What remains unproven |
|---|---|---|
| Fridays fulfillment disclaimer | How the company defines its success metric | Clinical effectiveness or individual results |
| Medication and pricing cards | Products and payment structures advertised | Final checkout amount or clinical suitability |
| Independent medication trials | Results for the studied interventions and populations | Outcomes for Fridays or its compounded products |
| Named pharmacy partners | Pharmacies listed in the terms | Which pharmacy will dispense a particular prescription |
| Subscription terms | Published billing and cancellation rules | How unresolved policy conflicts will be handled |
The product matters more than the ingredient shorthand
Fridays’ homepage advertises compounded semaglutide, compounded tirzepatide, Zepbound and Ozempic. Fridays identifies Zepbound as FDA-approved for chronic weight management and Ozempic as FDA-approved for type 2 diabetes; prescribing Ozempic for weight management is off-label. Its pricing page also displays Wegovy pill and pen memberships, while presenting injectable and oral options elsewhere without resolving every formulation detail in the available text. These listings establish advertised choices, not interchangeable products. Before comparing evidence or prices, a prospective patient needs the exact medicine, compounded or branded status, route, presentation and dispensing pharmacy attached to the proposed prescription.
Fridays states that it does not manufacture compounded medications and that received products and labels may differ from website images. It also discloses their lack of FDA approval. FDA explains that compounded preparations do not undergo its premarket review for safety, effectiveness and quality. That distinction is material, but nonapproval alone does not demonstrate clinical inequivalence. Approval belongs to a specific drug product; it is not a certification of Fridays, a clinician network or a pharmacy.
FDA recommends compounded drugs when an individual’s medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. That is a clinical discussion to have about the proposed preparation, not a conclusion this review can make for a reader. Our explanation of approved medicines and compounded preparations separates these evidence questions. The consulted records do not independently verify pharmacy credentials, manufacturing practices or the composition of a particular patient’s shipment.
Who evaluates patients—and who operates the platform
Thrive Health Group, Inc. is the legal entity operating Fridays. Its terms state that Fridays itself does not provide medical services. The homepage attributes clinical care to OpenLoop Healthcare Partners, PC and other networks, whose clinicians decide eligibility and may prescribe or decline compounded GLP-1 medication. Fridays describes its team as including physicians and licensed nurse practitioners. That is a provider description, not independent verification of the credentials of whichever clinician a patient ultimately sees.
Contractual access is limited to U.S. residents age 18 or older who have the capacity to enter the agreement. That does not establish availability of every product in every state: the microdosing page expressly says its program is not available in all 50 states. The consulted documentation does not supply a complete state-by-product list or identify every participating clinical network. A relevant prepayment question is which entity and clinician would actually provide care in the patient’s state.
Fridays publishes a BMI of 20 or higher as an entry baseline, not a guaranteed prescription. It separately lists possible exclusion circumstances, including pregnancy, breastfeeding, trying to become pregnant, end-stage kidney disease and end-stage liver disease. NIDDK describes general adult pharmacotherapy thresholds of BMI 30 or higher, or 27 or higher with weight-related health problems. The difference makes it especially important not to treat Fridays’ intake threshold as a medication indication or individualized eligibility determination.
From intake to follow-up: a documented outline, not a timetable
After the questionnaire, eligible applicants may arrange a prescription review with a video visit or, depending on their state, without one. Fridays says an initial appointment includes discussion of goals, medical-history review, any necessary laboratory orders and a possible prescription if appropriate. These are meaningful descriptions of the evaluation process. They do not establish a guaranteed prescription, a deadline for clinical review or a promised interval between paying, consulting and receiving medication.
The FAQ describes check-ins as usually monthly at first, covering progress, medication tolerance, laboratory follow-up, refills and care-plan changes. The pricing page separately advertises unlimited provider visits. Both statements can describe aspects of a service, but the documentation does not explain scheduling access or how unlimited visits relate to the usual cadence. Readers should distinguish an included visit benefit from an assurance of immediate appointments, rapid message responses or a particular clinician’s continuous availability.
Fridays lists CMP, HbA1c, TSH and a lipid panel among typical laboratory tests. One answer permits clinician acceptance of results up to 24 months old, while another mentions 12 months. Quest Diagnostics testing is described as included in the monthly subscription; testing elsewhere may cost extra. The practical question is what the assigned clinician requires and where coverage applies. Our guide to clinical follow-up beyond renewal notices explains why monitoring deserves attention separately from billing.
What the advertised prices do and do not buy
The compounded pricing blocks do not support one definitive rate. Semaglutide appears starting at $150 per month, paid annually and delivered monthly, with $249 per month stated for month-to-month enrollment. Tirzepatide appears starting at $240 per month on the annual-payment structure and $359 month-to-month. Other figures are interleaved within those blocks. Separate promotional copy advertises semaglutide at $99 or $150 monthly and tirzepatide as low as $198 or $240. None should be treated as universally available.
Branded injection cards are clearer on their face: Ozempic is listed at $1,498 per month and Zepbound at $1,828 per month, each month-to-month with unlimited provider visits, nutrition and mental-health coaching, and individual dietitian support. Wegovy pill and pen cards instead advertise a starting membership of $49 for the first month, explicitly excluding medication. Their footnote says subsequent membership can be as low as $98 per month with a prepaid annual plan. That is not a $49 ongoing medication price.
The four-month “Buy 3, get 1 free” offer is described as a 25% discount on the total four-month membership fee, collected once every four months and repeated at renewal. It is not an extra free shipment. General discount language elsewhere describes first-payment-only discounts, so the applicable offer needs written confirmation. Monthly delivery also does not establish transit time, supply quantity or a universal minimum commitment. The consulted pages do not resolve exact annual upfront totals or promotion compatibility.
Support benefits are documented; their delivery needs clarification
Fridays describes individual nutritionist support and ongoing chat access within the subscription, plus every-other-week meetings with a Certified Medical Assistant for goal setting and accountability. Its pricing page adds group coaching through Zoom, a SESH fitness-app membership and individual support from a dietitian and Journey Support coach. These are substantial advertised benefits, but the roles should not be collapsed into one clinical service. A coach or medical assistant is not interchangeable with a prescribing clinician.
The pricing page says all plans include unlimited provider visits and coaching, yet medication inclusion is not uniform: the Wegovy memberships expressly exclude medicine despite broader inclusion language elsewhere. This makes the selected product’s written benefit list more useful than a general “all included” impression. The records do not establish scheduling frequency for every support service, chat hours or response times. Nor do they show that advertised support, by itself, produces a measured Fridays-specific clinical benefit.
Fridays says insurance does not cover its compounded GLP-1 medications or the program’s virtual visits. It advertises prior-authorization assistance and permits HSA or FSA card payments for compounded medication, without establishing an individual’s coverage or tax treatment. Contact paths include support@joinfridays.com, ayuda@joinfridays.com and live chat. The Spanish-labeled email is useful contact information, but it does not confirm Spanish-language clinical visits. A prospective member should separately confirm language access, insurance expectations and any outside testing costs.
Pharmacy and delivery responsibilities remain partly unresolved
The terms name Red Rock Compounding Pharmacy, Health Warehouse, Precision Medicine and Triad Rx as pharmacy partners. Naming partners is useful, but it does not identify which one will dispense a particular prescription or establish that each listed pharmacy compounds every offered product. The documentation also leaves carrier, refrigeration arrangements, included supplies and possible shipping charges unresolved. These details matter when evaluating the actual product and service, rather than the platform’s overall marketing description.
Fridays requires immediate inspection of deliveries and contact with support within 24 hours for damaged or incorrect medication. Its standard remedy is replacement rather than refund, and medication generally becomes ineligible for return or refund once dispensed or shipped, except where law requires otherwise. Monthly delivery language supplies no concrete dispatch or arrival deadline. The records therefore support a problem-reporting process, not a verified promise about cold-chain performance or the speed of replacement.
FDA explicitly advises not using an injectable GLP-1 product that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy. Its reports of compounded-medication measurement errors also support clarifying instructions directly with those professionals, rather than calculating a dose from a review. Our guide to reading delivery and cold-chain claims separates shipping promises from safety evidence. Nothing in the consulted records establishes a Fridays-specific adverse-event rate or independently verifies its delivery performance.
Enrollment creates financial obligations before outcomes are known
The terms start the subscription and first billing cycle when enrollment is completed and medical intake is submitted for review. Cancellation is available through support@joinfridays.com or the account process if available, but Fridays must receive the request at least 72 hours before the next scheduled charge. Missing an appointment or cancelling it with less than 24 hours’ notice may generate a separate fee. Neither cancellation nor an unused benefit automatically establishes a right to a refund.
Refund language deserves particular attention. The terms allow refunds for medical disqualification before services begin, verified billing errors and legally required circumstances; switching programs may produce credit for the unused portion. Yet services begin at intake submission, creating tension with the broader promise of reimbursement when a clinician finds someone ineligible. The consulted terms also contain an omitted central portion. A prospective member should obtain written clarification about payment and ineligibility before submitting intake, rather than assume the apparent conflict resolves favorably.
The separate Forever Pricing policy protects the enrolled product’s monthly rate while the subscription remains continuously active. Cancellation permanently forfeits it. A patient-requested product or delivery-form change also loses that rate, whereas a clinician-directed change for intolerance, nonresponse or safety carries it forward. This is a conditional policy, not a universal price guarantee. It needs to be read alongside the exact selected offer, renewal interval and product terms—not used to reconcile every conflicting number on the pricing page.
Questions & answers
Does Fridays’ success rate show how much weight its patients lose?
No. Fridays defines that figure as recent internal fulfillment and delivery performance for paid orders. It expressly says the figure does not represent clinical outcomes or individual results. The consulted documentation does not establish a provider-specific weight-loss rate.
Is Fridays’ lowest advertised semaglutide price the standard monthly charge?
That cannot be established. The page displays $99 and $150 promotional monthly figures, a starting $150 monthly annual-payment offer and a stated $249 month-to-month price, alongside other interleaved numbers. Ask for the exact product, initial collection, renewal amount, billing interval and included services in writing.
Does the $49 Wegovy offer include medication?
No. The pill and pen cards explicitly exclude medication from the $49 first-month membership. Their footnote advertises subsequent membership as low as $98 monthly with a prepaid annual plan. The consulted text does not establish the separate medication charge or exact annual upfront collection.
Can an existing GLP-1 patient join for maintenance?
Fridays publishes maintenance criteria requiring a previous obesity diagnosis with BMI above 30 or overweight diagnosis with BMI above 27, plus GLP-1 use within the past 12 months. Those are provider criteria, not a promise of acceptance or a prescription; the clinician retains discretion after assessment.
Are laboratory tests included?
Fridays says testing at Quest Diagnostics is covered within its monthly subscription. Other locations may generate charges. Acceptance of previous results remains the clinician’s decision, and the FAQ mentions inconsistent 12- and 24-month windows. Confirm the required tests, acceptable prior results and testing location before arranging them.
How do I stop renewal, and will that produce a refund?
Contact support or use account cancellation if available, ensuring Fridays receives the request at least 72 hours before billing. Cancellation prevents a future cycle only when timely; it does not itself create a refund. Published refund exceptions are narrow, and dispensed or shipped medication generally cannot be refunded.
Our assessment
Fridays documents more than a medication checkout: it describes independent clinical evaluation, laboratory access, follow-up and several forms of coaching. It also makes useful disclosures about compounded products and the nonclinical meaning of its fulfillment metric. Those are meaningful strengths of the public record, not proof of treatment effectiveness. The main weaknesses are unresolved pricing overlaps, uneven inclusion language, an ambiguous ineligibility-refund boundary and incomplete product-specific pharmacy and delivery details. A reasonable comparison therefore depends on obtaining a written offer identifying the exact medicine and route, dispensing pharmacy, first charge, renewal structure, included services and cancellation rules. Clinical-trial evidence should be evaluated separately from those commercial terms. Fridays is a documented GLP-1 access platform, but the consulted pages do not establish that its particular preparations or service model deliver the outcomes seen in independent drug trials.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- Wilding et al. (2021): STEP 1 semaglutide trial ↗
- Jastreboff et al. (2022): SURMOUNT-1 tirzepatide trial ↗
- Fridays — microdosing ↗
- Fridays — pricing ↗
- Fridays — terms conditions ↗
- Fridays — official website ↗